Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 14, 2024; 30(34): 3862-3867
Published online Sep 14, 2024. doi: 10.3748/wjg.v30.i34.3862
Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma
Ronnakrit Trakoonsenathong, Ching-Feng Chiu, Charupong Saengboonmee
Ronnakrit Trakoonsenathong, Charupong Saengboonmee, Cho-Kalaphruek Excellent Research Project for Medical Students, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
Ronnakrit Trakoonsenathong, Charupong Saengboonmee, Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
Ronnakrit Trakoonsenathong, Charupong Saengboonmee, Center for Translational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
Ronnakrit Trakoonsenathong, Ching-Feng Chiu, Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei 11031, Taiwan
Author contributions: Trakoonsenathong R and Saengboonmee C conceptualized, reviewed, outlined, and wrote the first draft of the manuscript; Chiu CF and Saengboonmee C discussed and revised the manuscript; All authors reviewed and approved the final version of the manuscript.
Supported by Mekong - Lancang Cooperation Special Fund; Cho-Kalaphruek Excellent Research Project for Medical Students; and The International Internship Pilot Program, No. IIPP2023283.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Charupong Saengboonmee, MD, PhD, Assistant Professor, Department of Biochemistry, Faculty of Medicine, Khon Kaen University, 123 Mittraphap Highway, Khon Kaen 40002, Thailand. charusa@kku.ac.th
Received: May 26, 2024
Revised: August 19, 2024
Accepted: August 27, 2024
Published online: September 14, 2024
Processing time: 106 Days and 23.9 Hours
Core Tip

Core Tip: Glucagon-like peptide 1 receptor (GLP-1R) agonists, an anti-diabetic drug with other systemic benefits, have been reported for their association with increased risk of some cancers. Although the associations between GLP-1R agonists and the risk of cholangiocarcinoma (CCA) have not been consensus, the use of GLP-1R agonists showed the anti-tumor effects against CCA in vitro and animal models are evident. This editorial reviews and discusses recent studies of the effects of GLP-1R agonists both at epidemiological and molecular levels. The understanding of how GLP-1R agonist affects CCA will be beneficial for the management of patients with CCA and diabetes mellitus.